115 related articles for article (PubMed ID: 16309241)
21. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine.
Ngan VK; Bellman K; Hill BT; Wilson L; Jordan MA
Mol Pharmacol; 2001 Jul; 60(1):225-32. PubMed ID: 11408618
[TBL] [Abstract][Full Text] [Related]
22. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.
Mace AT; Harrow SJ; Ganly I; Brown SM
Acta Otolaryngol; 2007 Aug; 127(8):880-7. PubMed ID: 17763002
[TBL] [Abstract][Full Text] [Related]
23. Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review.
Gerullis H; Ecke T; Eimer C; Wishahi M; Otto T
Anticancer Drugs; 2011 Jan; 22(1):9-17. PubMed ID: 20948429
[TBL] [Abstract][Full Text] [Related]
24. Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro.
Simoens C; Lardon F; Pauwels B; De Pooter CM; Lambrechts HA; Pattyn GG; Breillout F; Vermorken JB
BMC Cancer; 2008 Feb; 8():65. PubMed ID: 18312675
[TBL] [Abstract][Full Text] [Related]
25. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.
Kruczynski A; Hill BT
Crit Rev Oncol Hematol; 2001 Nov; 40(2):159-73. PubMed ID: 11682323
[TBL] [Abstract][Full Text] [Related]
26. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
Jordan MA; Horwitz SB; Lobert S; Correia JJ
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
[TBL] [Abstract][Full Text] [Related]
27. Vinflunine: review of a new vinca alkaloid and its potential role in oncology.
Ng JS
J Oncol Pharm Pract; 2011 Sep; 17(3):209-24. PubMed ID: 20584744
[TBL] [Abstract][Full Text] [Related]
28. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.
Wang D; Veena MS; Stevenson K; Tang C; Ho B; Suh JD; Duarte VM; Faull KF; Mehta K; Srivatsan ES; Wang MB
Clin Cancer Res; 2008 Oct; 14(19):6228-36. PubMed ID: 18829502
[TBL] [Abstract][Full Text] [Related]
29. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
30. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development.
Kruczynski A; Poli M; Dossi R; Chazottes E; Berrichon G; Ricome C; Giavazzi R; Hill BT; Taraboletti G
Eur J Cancer; 2006 Nov; 42(16):2821-32. PubMed ID: 16973349
[TBL] [Abstract][Full Text] [Related]
31. Murine leukemia P388 vinorelbine-resistant cell lines are sensitive to vinflunine.
Aggarwal A; Kruczynski A; Frankfurter A; Correia JJ; Lobert S
Invest New Drugs; 2008 Aug; 26(4):319-30. PubMed ID: 18071633
[TBL] [Abstract][Full Text] [Related]
32. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation.
Yaromina A; Krause M; Thames H; Rosner A; Krause M; Hessel F; Grenman R; Zips D; Baumann M
Radiother Oncol; 2007 Jun; 83(3):304-10. PubMed ID: 17517444
[TBL] [Abstract][Full Text] [Related]
33. Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid.
Schutz FA; Bellmunt J; Rosenberg JE; Choueiri TK
Expert Opin Drug Saf; 2011 Jul; 10(4):645-53. PubMed ID: 21524237
[TBL] [Abstract][Full Text] [Related]
34. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
[TBL] [Abstract][Full Text] [Related]
35. Apoptotic mechanism of paclitaxel-induced cell death in human head and neck tumor cell lines.
Hsiao JR; Leu SF; Huang BM
J Oral Pathol Med; 2009 Feb; 38(2):188-97. PubMed ID: 19200178
[TBL] [Abstract][Full Text] [Related]
36. Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
Bellmunt J; Delgado FM; George C
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S34-43. PubMed ID: 18538178
[TBL] [Abstract][Full Text] [Related]
37. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Corvò R
Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
[TBL] [Abstract][Full Text] [Related]
38. Curcumin: a potential radio-enhancer in head and neck cancer.
Khafif A; Lev-Ari S; Vexler A; Barnea I; Starr A; Karaush V; Haif S; Ben-Yosef R
Laryngoscope; 2009 Oct; 119(10):2019-26. PubMed ID: 19655336
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
Hasegawa Y; Goto M; Hanai N; Ijichi K; Adachi M; Terada A; Hyodo I; Ogawa T; Furukawa T
Oral Oncol; 2007 Sep; 43(8):749-56. PubMed ID: 17112769
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma.
Hoebers FJ; Pameijer FA; de Bois J; Heemsbergen W; Balm AJ; Schornagel JH; Rasch CR
Head Neck; 2008 Sep; 30(9):1216-23. PubMed ID: 18642295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]